Loading...
Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer
BACKGROUND. We have already reported on fixed-dose-rate gemcitabine (FDR-Gem) in advanced, inoperable pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) in the context of a formal phase II study; building on that experience, we have now expanded the study to reach a cumulative ac...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AlphaMed Press
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227937/ https://ncbi.nlm.nih.gov/pubmed/20189980 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2008-0135 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|